MedTrace Logo

Investigation of the Passage of Antiviral Antibodies From Mother to Child

NCT05821764 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 4050

Last updated 2023-04-25

No results posted yet for this study

Summary

Infections remain a major cause of neonatal morbidity and mortality worldwide. At birth, multiple microorganisms, to which they are particularly vulnerable given the immaturity and naïve nature of their immune system, may infect newborns. Passive immunity by transplacental transfer of maternal antibodies is therefore of major importance in the first weeks and months of life before their own vaccination or until this period of immunological vulnerability has passed. Some factors are known to affect transplacental passage of antibodies but these have generally been studied in small series and many other parameters have not yet been investigated. The transmission rate of antibodies, particularly neutralizing antibodies, remains little explored, as well as the difference in transfer between antibodies induced by vaccination and those induced by natural infection, or the influence of maternal factors such as multiple pregnancy, other infections and treatment of these infections. A better identification and understanding of the factors that can affect transplacental transfer of maternal antibodies is crucial for optimization of vaccination strategies and close monitoring of particularly vulnerable newborns.

Conditions

  • Pregnant Woman
  • Adult Patient

Interventions

OTHER

Blood sample and data collection

Solicitation of parturients during a prenatal visit between 22 and 41 weeks of gestation or during their hospitalization in a high-risk pregnancy sector and at the latest on the day of their delivery. Blood sample : * Maternal sample within 72 hours before or after delivery during a care-based venipuncture (additional 10 mL sample) ; * The cord blood sample (10 mL) immediately after delivery. Data collection : * A data collection sheet for the attention of the investigator (doctor or midwife) ; * Additional data relating to the history of vaccination and infection completed by the patients included during their stay in the maternity ward and before their discharge from the hospital (Delay between 0 and 6 days after inclusion).

Sponsors & Collaborators

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • Christelle VAULOUP FELLOUS, Doctor · Paul Brousse Hospital

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-15
Primary Completion
2024-05-15
Completion
2024-08-15

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05821764 on ClinicalTrials.gov